Viking Therapeutics is trading 4.02% up now at $30.16, supported by a broad September 21, 2026 risk-on rally as major U.S. indices gained more than 0.5%.
- Oppenheimer reiterated an Outperform rating and $100 price target.
- The firm cited potential upside from upcoming VK2735 maintenance data.
- No company announcement explicitly tied the rating action to the intraday move; broader market sentiment appears the clearest driver.